Key Findings
The North America cystic fibrosis therapeutics market is estimated to register a CAGR of 10.07% over the projected period of 2020-2028. The market in North America is mainly driven by the presence of significant players in the biotechnology industry such as Vertex Pharmaceuticals Incorporated, Mylan N.V., and many others, who are investing mostly for the development of new technologies that can be used in the advancement of new testing techniques and improvement of the existing ones.

Market Insights
The cystic fibrosis therapeutics market of North America is segmented into the United States and Canada for further surveying growth in the region. In Canada, cystic fibrosis is the most common lethal hereditary disease affecting children and adolescents. It is calculated that out of every 3,600 children, one child has CF in Canada. The estimates show that the number of children, adolescents, and adults, with cystic fibrosis, attending specialized CF clinics, is more than 4,100, and approximately one in 25 Canadians carry an abnormal version of the gene responsible for causing cystic fibrosis. Canada is one of the emerging countries in North America, which holds approximately 11% share in the North American cystic fibrosis therapeutics market.
Further, Canada is one of the largest economies in the world, and its high healthcare expenditure, with universal healthcare sponsored through taxes, is among the best across the globe. Hence, increasing healthcare spending, along with the prevalence of this disease, is estimated to drive market growth. The market constraints in the North American region include monetary obstacles owing to the high cost of technology production.

Competitive Insights
AbbVie Inc, Abbott Laboratories, Agilent Technologies, Inc, Johnson & Johnson, Gilead Sciences, Inc, etc. are some of the renowned companies operating in the market.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments